Intracellular Sequestration of the NKG2D Ligand ULBP3 by Human Cytomegalovirus

被引:61
|
作者
Bennett, Neil J. [1 ]
Ashiru, Omodele [2 ]
Morgan, Fiona J. E. [1 ]
Pang, Yin [1 ]
Okecha, Georgina [1 ]
Eagle, Rob A. [3 ]
Trowsdale, John [3 ]
Sissons, J. G. Patrick [1 ]
Wills, Mark R. [1 ]
机构
[1] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England
[2] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England
[3] Univ Cambridge, Cambridge Inst Med Res, Cambridge, England
来源
JOURNAL OF IMMUNOLOGY | 2010年 / 185卷 / 02期
基金
英国惠康基金;
关键词
NATURAL-KILLER-CELLS; ACTIVATING RECEPTOR NKG2D; CLASS-I MOLECULES; T-CELLS; MOUSE CYTOMEGALOVIRUS; DOWN-REGULATION; NK CELLS; HLA-E; MURINE CYTOMEGALOVIRUS; SURFACE EXPRESSION;
D O I
10.4049/jimmunol.1000789
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human CMV (HCMV) encodes multiple genes that control NK cell activation and cytotoxicity. Some of these HCMV-encoded gene products modulate NK cell activity as ligands expressed at the cell surface that engage inhibitory NK cell receptors, whereas others prevent the infected cell from upregulating ligands that bind to activating NK cell receptors. A major activating NKR is the homodimeric NKG2D receptor, which has eight distinct natural ligands in humans. It was shown that HCMV is able to prevent the surface expression of five of these ligands (MIC A/B and ULBP1, 2, and 6). In this article, we show that the HCMV gene product UL142 can prevent cell surface expression of ULBP3 during infection. We further show that UL142 interacts with ULBP3 and mediates its intracellular retention in a compartment that colocalizes with markers of the cis-Golgi complex. In doing so, UL142 prevents ULBP3 trafficking to the surface and protects transfected cells from NK-mediated cytotoxicity. This is the first description of a viral gene able to mediate downregulation of ULBP3. The Journal of Immunology, 2010, 185: 1093-1102.
引用
收藏
页码:1093 / 1102
页数:10
相关论文
共 50 条
  • [1] ULBP4 is a novel ligand for human NKG2D
    Chalupny, NJ
    Sutherland, CL
    Lawrence, WA
    Rein-Weston, A
    Cosman, D
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 305 (01) : 129 - 135
  • [2] Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4
    Zoeller, Tobias
    Wittenbrink, Mareike
    Hoffmeister, Meike
    Steinle, Alexander
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [3] The NKG2D ligand ULBP4 is not expressed by human monocytes
    Lazarova, Mariya
    Kim, Younghoon
    Steinle, Alexander
    PLOS ONE, 2021, 16 (02):
  • [4] Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3
    Radaev, S
    Rostro, B
    Brooks, AG
    Colonna, M
    Sun, PD
    IMMUNITY, 2001, 15 (06) : 1039 - 1049
  • [5] Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor
    Lopez-Soto, Alejandro
    Quinones-Lombrana, Adolfo
    Lopez-Arbesu, Ruben
    Lopez-Larrea, Carlos
    Gonzalez, Segundo
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (41) : 30419 - 30430
  • [6] Intracellular Sequestration of the NKG2D Ligand MIC B by Species F Adenovirus
    Oliveira, Edson R. A.
    Li, Lenong
    Bouvier, Marlene
    VIRUSES-BASEL, 2021, 13 (07):
  • [7] ULBP6/RAET1L is an additional human NKG2D ligand
    Eagle, Robert A.
    Traherne, James A.
    Hair, James R.
    Jafferji, Insiya
    Trowsdale, John
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (11) : 3207 - 3216
  • [8] Four novel ULBP splice variants are ligands for human NKG2D
    Cao, Wei
    Xi, Xueyan
    Wang, Zhun
    Dong, Liling
    Hao, Zhiyong
    Cui, Lianxian
    Ma, Chi
    He, Wei
    INTERNATIONAL IMMUNOLOGY, 2008, 20 (08) : 981 - 991
  • [9] The NKG2D ligand ULBP4 binds to TCRγ9/δ2 and induces cytotoxicity to tumor cells through both TCRγδ and NKG2D
    Kong, Yan
    Cao, Wei
    Xi, Xueyan
    Ma, Chi
    Cui, Lianxian
    He, Wei
    BLOOD, 2009, 114 (02) : 310 - 317
  • [10] The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer
    Tan, Ge
    Spillane, Katelyn M.
    Maher, John
    BIOLOGY-BASEL, 2023, 12 (08):